Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07372508

Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions – Feasibility Study

Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions – Feasibility Study — Recruiting • Non-phase study • Oncology • NCT07372508.

📅 23 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07372508
Sponsor
NHS Greater Glasgow and Clyde
Start
2026-05-26
ClinicaliQ Trial Snapshot
  • Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions – Feasibility Study — Recruiting • Non-phase study • Oncology • NCT07372508.
  • What is being tested: Low-dose CT scanning combined with artificial intelligence diagnostics to detect lung cancer early and identify other cardio-respiratory long-term conditions in a Scottish population, assessing the feasibility of implementing this screening approach in NHS settings.
  • Patient eligibility overview: The study targets individuals at risk of lung cancer and cardio-respiratory disease in Glasgow, likely including current and former smokers and those with relevant risk factors, though specific inclusion criteria would be detailed in the full protocol.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier. Additional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart…

Eligibility Snapshot
  • : * Resident in South Sector NHS GG&C. * Capacity to undertake informed consent. * No active cancer other than non-melanoma skin cancer, monitored localised prostate cancer or localised treated breast cancer. * Aged 55-74 at date of invitation. * Smoking history: current tobacco smoker or ex-smoker with >20 pack year history and 200kg). * Unable to lie flat. * People who are pregnant. * Active symptoms of possible lung cancer

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Guideline
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Oncology · 14 Jul 2026
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as…
View guideline →
Guideline
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Oncology · 24 Jun 2026
Mirvetuximab soravtansine is recommended for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with folate receptor-alpha (FRα) positivity—confirm FRα…
View guideline →
Clinical Brief
Are current breast cancer checks good enough?
Oncology · BBC Health · 04 Aug 2026
Current breast cancer screening pathways fail to identify up to 95% of younger women at genuinely higher risk, suggesting substantial gaps in…
View brief →